Clinical trials: Esophagogastric Adenocarcinoma
Gastric Adenocarcinoma, Pancreatic Cancer
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic…
- Conditions
- Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04581473
- Testing
- CT041 autologous CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- Where
- 24 sites in China
- Volunteers
- 192 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to…
- Conditions
- Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Trial name
- PROXISTAT (NCT07441785)
- Testing
- Proximal Gastrectomy
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- P. Herzen Moscow Oncology Research Institute
Adenocarcinomas of the Esophagogastric Junction
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)
Prospective, single-center, nonrandomized, explorative imaging study evaluating the value of PET as a predictor of histopathological response in metabolic non-responders Patients with resectable AEG (adenocarcinoma of the…
- Trial name
- HICON (NCT01271322)
- Testing
- neoadjuvant radiochemotherapy in metabolic non responders
- Where
- Germany
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Malignant Neoplasm of Stomach
Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients
Patients with histological proven advanced gastric cancer (including cancer of the esophagogastric junction (AEG) without evidence of distant metastases, who fulfill the inclusion and exclusion criteria, can be recruited in this…
- Trial name
- NCT02381847
- Testing
- intraperitoneal chemoperfusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Immunotherapy Gastroesophageal Junction
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
- Trial name
- NCT06396585
- Testing
- Tislelizumab, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
Stomach Neoplasms, Peritoneal Metastases
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include "cT4aNxM0, P0 or cTxNxM1, P1" patients with gastric or esophagogastric junction adenocarcinoma, to evaluate the efficacy and safety of…
- Trial name
- NCT05095467
- Testing
- HIPEC, Paclitaxel-albumin, Tegafur-gimeracil-oteracil potassium
- Volunteers
- 157 people
- Sponsor
- Xuefei.Wang
OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Oesophageal Cancer Nos
- Trial name
- AROMA2 (NCT07260734)
- Testing
- Breath Test
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Esophageal Cancer, Gastric Cancer
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin…
- Trial name
- NCT00113581
- Testing
- EMD 72000 (matuzumab) + ECX
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Adenocarcinoma of Stomach or Esophagogastric Junction
Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer
Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in gastric cancer , the present clinical study to…
- Trial name
- GC-CIF-2005 (NCT01123811)
- Testing
- Cetuximab IF
- Where
- 10 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Johannes Gutenberg University Mainz
Esophagogastric Adenocarcinoma
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
- Trial name
- NCT06123468
- Testing
- Sacituzumab govitecan
- Where
- 8 sites in Austria, Germany
- Volunteers
- 58 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophageal Neoplasm, Gastric Neoplasm
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
The prognosis for patients with advanced oesophago-gastric cancer is poor. Approximately 16,000 patients in the United Kingdom die from the disease.
- Trial name
- NCT01870791
- Testing
- Omegaven
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University Hospitals, Leicester
Gastric Carcinoma Stage IV, Esophagogastric Junction Adenocarcinoma Stage IV
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
Patients with metastatic adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations .
- Trial name
- IRIGA (NCT04442984)
- Testing
- Irinotecan, Oxaliplatin, 5-FU
- Where
- Russia
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Esophagogastric Tumors, Gastric Cancer
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.
- Conditions
- Esophagogastric Tumors, Gastric Cancer, Gastric Tumor, Esophageal Cancer
- Trial name
- NCT04510285
- Testing
- Trastuzumab, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
- Trial name
- NCT01956149
- Testing
- Cabazitaxel
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
CAR T-Cell Therapy
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects.
- Trial name
- NCT05277987
- Testing
- HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T Cells)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Fifth People's Hospital
Esophageal Cancer, Adenocarcinoma of the Esophagus
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
Both neoadjuvant chemoradiotherapy (CROSS) and neoadjuvant chemotherapy (FLOT) have demonstrated overall survival benefit over surgery alone in esophageal and esophagogastric junction (EGJ) cancer.
- Trial name
- TNT-OES-2 (NCT06161818)
- Testing
- FLOT-CROSS or CROSS-FLOT
- Where
- 10 sites in Netherlands
- Volunteers
- 216 people
- Sponsor
- Erasmus Medical Center
Adenocarcinoma
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work…
- Trial name
- NCT02213289
- Testing
- Trastuzumab, ABT-806, Bemarituzumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Oesophagogastric Cancer
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ST03 (NCT00450203)
- Testing
- bevacizumab, capecitabine, cisplatin
- Where
- 41 sites in United Kingdom
- Volunteers
- 1,103 people
- Sponsor
- Professor David Cunningham
HER2 Positive Esophagogastric Cancer
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
With improvements in response rate and survival seen for HER2 positive patients treated with HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting to increase antitumor effect shows promise.
- Trial name
- NCT01769508
- Testing
- 5-Fluorouracil, Oxaliplatin, Lapatinib
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- SCRI Development Innovations, LLC
Gastric Cancer, Esophagogastric Junction Adenocarcinoma
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a…
- Trial name
- NCT06461910
- Testing
- Serplulimab, thymalfasin, Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zekuan Xu